Publications by authors named "Bryce M Waldman"
The field of hematopoietic cell transplantation and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant diseases. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- Patients with advanced myelodysplastic syndromes (MDS) have a better chance of living longer with a bone marrow transplant (BMT) compared to other treatments, but only 15% currently receive this option.
- Experts recommend collaboration between community doctors, transplant specialists, insurance companies, and patient advocacy groups to raise awareness about BMT's benefits and address financial and logistical barriers.
- Goals of this collaboration include ensuring affordable healthcare, providing emotional support, assisting with transportation and housing for transplant-related travel, and improving care for under-represented racial and ethnic communities.